{"title":"Beckenbodeneingriffe: höchstes Risiko nach Vaginalgeburt","authors":"","doi":"10.1055/a-2175-5313","DOIUrl":"https://doi.org/10.1055/a-2175-5313","url":null,"abstract":"","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"16 6","pages":""},"PeriodicalIF":2.7,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139205525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-30eCollection Date: 2023-12-01DOI: 10.1055/a-2177-0290
Lena Strößner, Yvonne Heimann, Ekkehard Schleußner, Anna Kolterer
Introduction: Induction of labour is a common obstetric procedure to initiate or augment contractions when labour is delayed or uncertain. The double balloon catheter is a safe and effective mechanical method for cervical ripening during induction of labour. This study evaluates the effectiveness of reducing double balloon catheter insertion time from 12 to 6 hours.
Methods: 248 women undergoing induction with a double balloon catheter at term were divided into two groups: catheter placed for 12 hours at 8 pm in the first half of 2021 (P12) and catheter placed for 6 hours at 7 am in the second half of 2021 (P6). T-tests, chi-squared tests, and Wilcoxon signed rank test were used for statistical analysis. Primary and secondary endpoints included induction to delivery interval, prostaglandin to delivery interval, mode of delivery, and maternal and neonatal outcomes.
Results: The P6 group had a significantly reduced induction to delivery interval of 558 min (P6: 1348 min, P12: 1906 min, p < 0.01, 95% CI: 376-710) within demographically comparable groups. Multiparous women also showed a significant reduction in prostaglandin to delivery interval of 260 min (P6: 590 min, P12: 850 min, p = 0.038, 95% CI: 9-299). There were no significant differences in mode of delivery, maternal blood loss, or neonatal outcome.
Conclusion: Reducing double balloon catheter placement time from 12 to 6 hours resulted in almost 9 hours less induction to delivery interval without adverse effects on maternal and neonatal outcome.
导言:引产是一种常见的产科程序,用于在分娩延迟或不确定时启动或增强宫缩。双气囊导尿管是引产过程中宫颈成熟的一种安全有效的机械方法。本研究评估将双球囊导管插入时间从12小时减少到6小时的有效性。方法:248例足月行双球囊导尿管诱导的妇女分为两组:2021年上半年晚上8点放置导尿管12小时(P12), 2021年下半年早上7点放置导尿管6小时(P6)。采用t检验、卡方检验和Wilcoxon符号秩检验进行统计分析。主要和次要终点包括诱导分娩间隔、前列腺素至分娩间隔、分娩方式以及产妇和新生儿结局。结果:P6组诱导分娩间隔时间明显缩短558 min (P6: 1348 min, P12: 1906 min, p)。结论:双球囊置管时间由12小时缩短至6小时,诱导分娩间隔时间缩短近9小时,对产妇及新生儿预后无不良影响。
{"title":"Induction of Labour with a Double Balloon Catheter - Comparison of Effectiveness of Six Versus Twelve Hours Insertion Time: a Prospective Case Control Study.","authors":"Lena Strößner, Yvonne Heimann, Ekkehard Schleußner, Anna Kolterer","doi":"10.1055/a-2177-0290","DOIUrl":"10.1055/a-2177-0290","url":null,"abstract":"<p><strong>Introduction: </strong>Induction of labour is a common obstetric procedure to initiate or augment contractions when labour is delayed or uncertain. The double balloon catheter is a safe and effective mechanical method for cervical ripening during induction of labour. This study evaluates the effectiveness of reducing double balloon catheter insertion time from 12 to 6 hours.</p><p><strong>Methods: </strong>248 women undergoing induction with a double balloon catheter at term were divided into two groups: catheter placed for 12 hours at 8 pm in the first half of 2021 (P12) and catheter placed for 6 hours at 7 am in the second half of 2021 (P6). T-tests, chi-squared tests, and Wilcoxon signed rank test were used for statistical analysis. Primary and secondary endpoints included induction to delivery interval, prostaglandin to delivery interval, mode of delivery, and maternal and neonatal outcomes.</p><p><strong>Results: </strong>The P6 group had a significantly reduced induction to delivery interval of 558 min (P6: 1348 min, P12: 1906 min, p < 0.01, 95% CI: 376-710) within demographically comparable groups. Multiparous women also showed a significant reduction in prostaglandin to delivery interval of 260 min (P6: 590 min, P12: 850 min, p = 0.038, 95% CI: 9-299). There were no significant differences in mode of delivery, maternal blood loss, or neonatal outcome.</p><p><strong>Conclusion: </strong>Reducing double balloon catheter placement time from 12 to 6 hours resulted in almost 9 hours less induction to delivery interval without adverse effects on maternal and neonatal outcome.</p>","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"83 12","pages":"1500-1507"},"PeriodicalIF":2.7,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689105/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138477278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Präeklampsie: Ist das Absetzen von ASS bei unauffälligem Doppler vertretbar?","authors":"","doi":"10.1055/a-2175-5439","DOIUrl":"https://doi.org/10.1055/a-2175-5439","url":null,"abstract":"","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":" 47","pages":""},"PeriodicalIF":2.7,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139207299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Vaginale Hysteropexie vs. Hysterektomie mit apikaler Suspension","authors":"","doi":"10.1055/a-2175-5467","DOIUrl":"https://doi.org/10.1055/a-2175-5467","url":null,"abstract":"","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"61 3","pages":""},"PeriodicalIF":2.7,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139206221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Überschüssiges Probenmaterial darf anonymisiert für weitere Zwecke (z. B. wissenschaftliche Fragestellungen, Lehre, allgemeine Qualitätssicherung) ohne zeitliche Befristung aufbewahrt werden. Ich bin damit einverstanden, dass im Hinblick auf die o.g. Erkrankung / Störung / Diagnose eine genetische Untersuchung bei mir, meinem Kind oder der von mir betreuten Person durchgeführt wird. Über die Aussagemöglichkeiten und -grenzen der genetischen Diagnostik sowie mein Recht auf Nichtwissen der Untersuchungsergebnisse bin ich aufgeklärt worden. Untersuchungsmaterial Heparin-Vollblut DNA ____________________ Abnahmedatum: Genetische Diagnostik in der Reproduktionsmedizin
多余的样本材料可匿名保存,以用于进一步的目的(如科学问题、教学、一般质量保 证),没有任何时间限制。我同意对我、我的子女或我所照顾的人进行与上述疾病/失调/诊断有关的基因检测。我已被告知基因诊断的可能性和局限性以及我不知道检测结果的权利。检测材料 肝素全血 DNA ____________________ 采集日期: 生殖医学基因诊断
{"title":"Genetische Diagnostik in der Reproduktionsmedizin","authors":"","doi":"10.1055/a-2175-5341","DOIUrl":"https://doi.org/10.1055/a-2175-5341","url":null,"abstract":"Überschüssiges Probenmaterial darf anonymisiert für weitere Zwecke (z. B. wissenschaftliche Fragestellungen, Lehre, allgemeine Qualitätssicherung) ohne zeitliche Befristung aufbewahrt werden. Ich bin damit einverstanden, dass im Hinblick auf die o.g. Erkrankung / Störung / Diagnose eine genetische Untersuchung bei mir, meinem Kind oder der von mir betreuten Person durchgeführt wird. Über die Aussagemöglichkeiten und -grenzen der genetischen Diagnostik sowie mein Recht auf Nichtwissen der Untersuchungsergebnisse bin ich aufgeklärt worden. Untersuchungsmaterial Heparin-Vollblut DNA ____________________ Abnahmedatum: Genetische Diagnostik in der Reproduktionsmedizin","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"67 4","pages":""},"PeriodicalIF":2.7,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139196974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Amanda Klee, N. Amann, C. Becker, P. Fößleitner, N. Krawczyk, Rama Kiblawi, Solveig Simowitsch, Nikolas Tauber, N. Taumberger, Maggie Banys-Paluchowski
{"title":"Teilnahme-Aufruf – Favorisierte Arbeitszeitmodelle in der Gynäkologie – FARBEN-Studie der Jungen Foren DGGG, OEGGG und SGGG","authors":"Amanda Klee, N. Amann, C. Becker, P. Fößleitner, N. Krawczyk, Rama Kiblawi, Solveig Simowitsch, Nikolas Tauber, N. Taumberger, Maggie Banys-Paluchowski","doi":"10.1055/a-2173-1434","DOIUrl":"https://doi.org/10.1055/a-2173-1434","url":null,"abstract":"","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"8 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139198911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Diagnose und Therapie ektoper Schwangerschaften außerhalb der Tube","authors":"","doi":"10.1055/a-2175-5355","DOIUrl":"https://doi.org/10.1055/a-2175-5355","url":null,"abstract":"","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"33 8","pages":""},"PeriodicalIF":2.7,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139200450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-30eCollection Date: 2023-12-01DOI: 10.1055/a-2196-6224
Marina Sourouni, Ariane Germeyer, Manuel Feißt, Alexandra Balzer, Helen Köster, Annemarie Minte, Dörthe Brüggmann, Celine Kohll, Kristin Reinhardt, Michaela Möginger, Anja Leonhardt, Constanze Banz-Jansen, Michael Bohlmann, Christiane Fröhlich, Clara Backes, Dietrich Hager, Lisa Kaup, Elsa Hollatz-Galuschki, Charlotte Engelbrecht, Filiz Markfeld-Erol, Carsten Hagenbeck, Hening Schäffler, Jennifer Winkler, Johannes Stubert, Katharina Rathberger, Laura Lüber, Linda Hertlein, Antonia Machill, Manuela Richter, Martin Berghäuser, Michael Weigel, Mirjam Morgen, Nora Horn, Peter Jakubowski, Bastian Riebe, Babett Ramsauer, Robert Sczesny, Ute Margaretha Schäfer-Graf, Susanne Schrey, Sven Kehl, Julia Lastinger, Sven Seeger, Olaf Parchmann, Antonella Iannaccone, Jens Rohne, Luise Gattung, Christine A Morfeld, Michael Abou-Dakn, Markus Schmidt, Michaela Glöckner, Anja Jebens, Kathleen Marie Sondern, Ulrich Pecks, Ralf Schmitz, Mareike Möllers
Introduction: Studies have shown that pregnant women with COVID-19 have a higher risk of intensive care unit admission and invasive mechanical ventilation support than non-pregnant women. Pregnancy-associated physiological changes in respiratory function may contribute to the elevated risk. Alteration in lung volumes and capacities are attributed to the mechanical impediment caused by the growing fetus. Multiple pregnancies may therefore compromise functional lung capacity earlier than singleton pregnancies and contribute to severe respiratory symptoms of COVID-19.
Materials and methods: A total of 5514 women with a symptomatic SARS-CoV-2 infection during pregnancy registered in the COVID-19 Related Obstetric and Neonatal Outcome Study were included. The COVID-19-related adverse maternal outcomes were compared in 165 multiple versus 5349 singleton pregnancies. Combined adverse maternal outcome was defined as presence of COVID-19-related hospitalization and/or pneumonia and/or oxygen administration and/or transfer to ICU and/or death. Multivariate logistic regression was used to estimate the odds ratios and 95% confidence intervals were calculated.
Results: The frequency of dyspnea, likelihood of developing dyspnea in a defined pregnancy week and duration of the symptomatic phase of the COVID-19 infection did not differ between the two groups. On average, COVID-19-related combined adverse outcome occurred earlier during pregnancy in women expecting more than one child than in singleton pregnancies. The overall incidence of singular and combined COVID-19-associated adverse maternal outcomes was not significantly different between groups. However, regression analysis revealed that multiple gestation, preconceptional BMI > 30 kg/m 2 and gestational age correlated significantly with an increased risk of combined adverse maternal outcome. Conversely, maternal age and medically assisted reproduction were not significant risk factors for combined adverse maternal outcome.
Conclusion: Our data show that multiple gestation alone is a risk factor for COVID-19-associated combined adverse maternal outcome. Moreover, severe courses of COVID-19 in women expecting more than one child are observed earlier in pregnancy than in singleton pregnancies.
{"title":"Multiple Gestation as a Risk Factor for SARS-CoV-2-Associated Adverse Maternal Outcome: Data From the COVID-19 Related Obstetric and Neonatal Outcome Study (CRONOS).","authors":"Marina Sourouni, Ariane Germeyer, Manuel Feißt, Alexandra Balzer, Helen Köster, Annemarie Minte, Dörthe Brüggmann, Celine Kohll, Kristin Reinhardt, Michaela Möginger, Anja Leonhardt, Constanze Banz-Jansen, Michael Bohlmann, Christiane Fröhlich, Clara Backes, Dietrich Hager, Lisa Kaup, Elsa Hollatz-Galuschki, Charlotte Engelbrecht, Filiz Markfeld-Erol, Carsten Hagenbeck, Hening Schäffler, Jennifer Winkler, Johannes Stubert, Katharina Rathberger, Laura Lüber, Linda Hertlein, Antonia Machill, Manuela Richter, Martin Berghäuser, Michael Weigel, Mirjam Morgen, Nora Horn, Peter Jakubowski, Bastian Riebe, Babett Ramsauer, Robert Sczesny, Ute Margaretha Schäfer-Graf, Susanne Schrey, Sven Kehl, Julia Lastinger, Sven Seeger, Olaf Parchmann, Antonella Iannaccone, Jens Rohne, Luise Gattung, Christine A Morfeld, Michael Abou-Dakn, Markus Schmidt, Michaela Glöckner, Anja Jebens, Kathleen Marie Sondern, Ulrich Pecks, Ralf Schmitz, Mareike Möllers","doi":"10.1055/a-2196-6224","DOIUrl":"10.1055/a-2196-6224","url":null,"abstract":"<p><strong>Introduction: </strong>Studies have shown that pregnant women with COVID-19 have a higher risk of intensive care unit admission and invasive mechanical ventilation support than non-pregnant women. Pregnancy-associated physiological changes in respiratory function may contribute to the elevated risk. Alteration in lung volumes and capacities are attributed to the mechanical impediment caused by the growing fetus. Multiple pregnancies may therefore compromise functional lung capacity earlier than singleton pregnancies and contribute to severe respiratory symptoms of COVID-19.</p><p><strong>Materials and methods: </strong>A total of 5514 women with a symptomatic SARS-CoV-2 infection during pregnancy registered in the COVID-19 Related Obstetric and Neonatal Outcome Study were included. The COVID-19-related adverse maternal outcomes were compared in 165 multiple versus 5349 singleton pregnancies. Combined adverse maternal outcome was defined as presence of COVID-19-related hospitalization and/or pneumonia and/or oxygen administration and/or transfer to ICU and/or death. Multivariate logistic regression was used to estimate the odds ratios and 95% confidence intervals were calculated.</p><p><strong>Results: </strong>The frequency of dyspnea, likelihood of developing dyspnea in a defined pregnancy week and duration of the symptomatic phase of the COVID-19 infection did not differ between the two groups. On average, COVID-19-related combined adverse outcome occurred earlier during pregnancy in women expecting more than one child than in singleton pregnancies. The overall incidence of singular and combined COVID-19-associated adverse maternal outcomes was not significantly different between groups. However, regression analysis revealed that multiple gestation, preconceptional BMI > 30 kg/m <sup>2</sup> and gestational age correlated significantly with an increased risk of combined adverse maternal outcome. Conversely, maternal age and medically assisted reproduction were not significant risk factors for combined adverse maternal outcome.</p><p><strong>Conclusion: </strong>Our data show that multiple gestation alone is a risk factor for COVID-19-associated combined adverse maternal outcome. Moreover, severe courses of COVID-19 in women expecting more than one child are observed earlier in pregnancy than in singleton pregnancies.</p>","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"83 12","pages":"1508-1518"},"PeriodicalIF":2.4,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689107/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138477279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-22eCollection Date: 2024-01-01DOI: 10.1055/a-2192-2998
Annika Behrens, Lena Wurmthaler, Felix Heindl, Paul Gass, Lothar Häberle, Bernhard Volz, Carolin C Hack, Julius Emons, Ramona Erber, Arndt Hartmann, Matthias W Beckmann, Matthias Ruebner, William C Dougall, Michael F Press, Peter A Fasching, Hanna Huebner
Introduction: The receptor activator of nuclear factor-κB (RANK) pathway was associated with the pathogenesis of breast cancer. Several studies attempted to link the RANK/RANKL pathway to prognosis; however, with inconsistent outcomes. We aimed to further contribute to the knowledge about RANK/RANKL as prognostic factors in breast cancer. Within this study, protein expression of RANK and its ligand, RANKL, in the tumor tissue was analyzed in association with disease-free survival (DFS) and overall survival (OS) in a study cohort of patients with early breast cancer.
Patients and methods: 607 samples of female primary and early breast cancer patients from the Bavarian Breast Cancer Cases and Controls Study were analyzed to correlate the RANK and RANKL expression with DFS and OS. Therefore, expression was quantified using immunohistochemical staining of a tissue microarray. H-scores were determined with the cut-off value of 8.5 for RANK and 0 for RANKL expression, respectively.
Results: RANK and RANKL immunohistochemistry were assessed by H-score. Both biomarkers did not correlate (ρ = -0.04). According to molecular subtypes, triple-negative tumors and HER2-positive tumors showed a higher number of RANK-positive tumors (H-score ≥ 8.5), however, no subtype-specific expression of RANKL could be detected. Higher RANKL expression tended to correlate with a better prognosis. However, RANK and RANKL expression could not be identified as statistically significant prognostic factors within the study cohort.
Conclusions: Tumor-specific RANK and RANKL expressions are not applicable as prognostic factors for DFS and OS, but might be associated with subtype-specific breast cancer progression.
{"title":"RANK and RANKL Expression in Tumors of Patients with Early Breast Cancer.","authors":"Annika Behrens, Lena Wurmthaler, Felix Heindl, Paul Gass, Lothar Häberle, Bernhard Volz, Carolin C Hack, Julius Emons, Ramona Erber, Arndt Hartmann, Matthias W Beckmann, Matthias Ruebner, William C Dougall, Michael F Press, Peter A Fasching, Hanna Huebner","doi":"10.1055/a-2192-2998","DOIUrl":"10.1055/a-2192-2998","url":null,"abstract":"<p><strong>Introduction: </strong>The receptor activator of nuclear factor-κB (RANK) pathway was associated with the pathogenesis of breast cancer. Several studies attempted to link the RANK/RANKL pathway to prognosis; however, with inconsistent outcomes. We aimed to further contribute to the knowledge about RANK/RANKL as prognostic factors in breast cancer. Within this study, protein expression of RANK and its ligand, RANKL, in the tumor tissue was analyzed in association with disease-free survival (DFS) and overall survival (OS) in a study cohort of patients with early breast cancer.</p><p><strong>Patients and methods: </strong>607 samples of female primary and early breast cancer patients from the Bavarian Breast Cancer Cases and Controls Study were analyzed to correlate the RANK and RANKL expression with DFS and OS. Therefore, expression was quantified using immunohistochemical staining of a tissue microarray. H-scores were determined with the cut-off value of 8.5 for RANK and 0 for RANKL expression, respectively.</p><p><strong>Results: </strong>RANK and RANKL immunohistochemistry were assessed by H-score. Both biomarkers did not correlate (ρ = -0.04). According to molecular subtypes, triple-negative tumors and HER2-positive tumors showed a higher number of RANK-positive tumors (H-score ≥ 8.5), however, no subtype-specific expression of RANKL could be detected. Higher RANKL expression tended to correlate with a better prognosis. However, RANK and RANKL expression could not be identified as statistically significant prognostic factors within the study cohort.</p><p><strong>Conclusions: </strong>Tumor-specific RANK and RANKL expressions are not applicable as prognostic factors for DFS and OS, but might be associated with subtype-specific breast cancer progression.</p>","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"84 1","pages":"77-85"},"PeriodicalIF":2.7,"publicationDate":"2023-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10764119/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139097711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}